Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Inogen Inc

INGN Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2016–FY2025

Last close · Oct 23, 2026

$7.10

0.9%
Compare
Revenue Total sales reported in the income statement.
$349M
3.9% vs prior year
Operating margin Operating income as a share of revenue.
−8.7%
4.0 pts
Net income Profit after all expenses, interest and tax.
−$22.7M
Free cash flow Cash from operations minus capital spending.
−$13.7M
637.9%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$192M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$0.90 EPS (TTM)

What Inogen Inc does

No business description yet.

Legal name
Inogen Inc
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 27, 2026
Accession · CIK
0001193125-26-082630
0001294133

Revenue and margins

Inogen Inc had $349M of revenue in fiscal 2025, up 3.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$13.7M in fiscal 2025, −3.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Inogen Inc returned — to shareholders in fiscal 2025. The diluted share count rose 12.5%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Inogen Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $246M$187M$128M$114M$120M
Current ratio 5.4x4.7x2.9x2.4x3.1x
Quick ratio 4.8x4.1x2.6x2.1x2.7x
Total assets $490M$405M$326M$296M$299M
Total liabilities $119M$108M$121M$122M$106M
Shareholders' equity $370M$297M$205M$174M$192M
Net debt (− = net cash) —————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✓ ✕
Return on assets rose — ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — — — — — — — — —
Current ratio rose — ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✓
Share count didn't rise — ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ ✕
Gross margin rose — ✓ ✓ ✕ ✕ ✓ ✕ ✕ ✓ ✕
Revenue rose relative to assets — ✕ ✓ ✕ ✕ ✓ ✓ ✓ ✓ ✓
F-score — / 34 / 87 / 84 / 83 / 84 / 82 / 82 / 85 / 84 / 8
Accruals ratio −4.9%−16.1%−2.5%−4.8%−9.4%−6.3%−10.3%−27.1%−13.4%−3.9%
Altman Z'' 10.7610.3810.867.967.177.435.251.061.252.26

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $203M $249M $358M $362M $308M $358M $377M $316M $336M $349M
Gross profit $97.3M $121M $179M $172M $138M $176M $154M $127M $155M $154M
Research and development $5.1M $5.3M $7.0M $9.4M $14.1M $16.6M $21.9M $20.8M $21.6M $19.4M
Operating income $22.9M $27.6M $37.9M $19.8M −$12.0M $9.2M −$85.2M −$109M −$42.5M −$30.2M
Interest expense $0.0M — — — — — — — — —
Pretax income $22.7M $29.7M $40.5M $24.3M −$5.3M $8.7M −$83.3M −$102M −$36.5M −$23.4M
Income tax $2.2M $8.7M −$11.4M $3.3M $0.5M $15.0M $0.5M $0.1M −$0.6M −$0.6M
Net income $20.5M $21.0M $51.8M $21.0M −$5.8M −$6.3M −$83.8M −$102M −$35.9M −$22.7M
Diluted EPS $0.97 $0.96 $2.30 $0.94 −$0.27 −$0.28 −$3.67 −$4.42 −$1.52 −$0.86
Diluted shares 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.03B
Cash flow
Cash from operations $31.0M $60.5M $60.0M $40.6M $37.0M $23.6M −$37.5M −$3.2M $5.9M −$11.2M
Capital expenditure $1.7M $2.9M $8.0M $3.1M $4.4M $5.5M $3.3M $5.2M $3.4M $2.5M
Free cash flow $29.3M $57.6M $51.9M $37.5M $32.6M $18.2M −$40.9M −$8.5M $2.6M −$13.7M
Depreciation and amortization $13.6M $12.3M $11.3M $13.8M $18.6M $21.6M $23.5M $18.2M $21.0M $20.7M
Stock-based compensation $7.3M $9.6M $12.8M $9.1M $8.2M $10.9M $12.3M $7.4M $7.4M $8.0M
Acquisitions — $4.5M — $70.4M — — — $29.6M — —
Balance sheet
Cash and short-term investments $114M $174M $240M $209M $231M $246M $187M $128M $114M $120M
Current assets $162M $228M $315M $292M $306M $329M $305M $207M $185M $198M
Current liabilities $22.8M $33.9M $46.6M $50.2M $56.7M $61.5M $65.3M $72.5M $76.7M $63.5M
Inventory $14.3M $18.8M $27.1M $35.7M $24.8M $31.9M $34.1M $21.8M $24.8M $26.0M
Property and equipment, net $25.2M $20.1M $22.3M $19.4M $28.2M $38.9M $43.3M $50.3M $44.4M $36.4M
Goodwill — $2.4M $2.3M $33.0M $33.2M $33.0M $32.9M $10.1M $9.5M $10.7M
Intangible assets $0.2M $4.7M $3.8M $77.5M $68.8M $60.1M $0.2M $34.6M $30.5M $30.8M
Total assets $214M $275M $376M $447M $462M $490M $405M $326M $296M $299M
Total liabilities $32.0M $48.0M $65.5M $103M $112M $119M $108M $121M $122M $106M
Shareholders' equity $182M $227M $310M $345M $350M $370M $297M $205M $174M $192M
Margins
Gross margin 48.0% 48.6% 49.9% 47.5% 44.8% 49.3% 40.7% 40.1% 46.1% 44.2%
Operating margin 11.3% 11.1% 10.6% 5.5% −3.9% 2.6% −22.6% −34.7% −12.7% −8.7%
EBITDA margin 18.0% 16.0% 13.7% 9.3% 2.1% 8.6% −16.4% −28.9% −6.4% −2.7%
Net margin 10.1% 8.4% 14.5% 5.8% −1.9% −1.8% −22.2% −32.5% −10.7% −6.5%
FCF margin 14.5% 23.1% 14.5% 10.3% 10.6% 5.1% −10.8% −2.7% 0.8% −3.9%
Returns
Return on capital employed 12.0% 11.4% 11.5% 5.0% −3.0% 2.2% −25.1% −43.1% −19.4% −12.8%
Return on equity 11.3% 10.3% 19.3% 6.4% −1.7% −1.8% −25.1% −40.8% −19.0% −12.4%
Return on assets 9.6% 8.6% 15.9% 5.1% −1.3% −1.3% −18.7% −28.0% −11.5% −7.6%
Return on tangible equity 11.3% 9.5% 17.0% 8.9% −2.4% −2.3% −31.7% −64.0% −26.8% −15.1%
Growth
Revenue growth — 23.0% 43.6% 1.1% −14.8% 16.1% 5.4% −16.3% 6.4% 3.9%
Net income growth — 2.4% 146.9% −59.6% −127.8% — — — — —
EPS growth — −1.0% 139.6% −59.1% −128.7% — — — — —
FCF growth — 96.4% −9.8% −27.9% −12.9% −44.4% −325.2% — — −637.9%
Share count change — 3.8% 2.8% −1.2% −1.2% 2.3% 1.6% 1.4% 2.1% 12.5%
Financial health
Interest coverage 3,810.7x — — — — — — — — —
Current ratio 7.1x 6.7x 6.8x 5.8x 5.4x 5.4x 4.7x 2.9x 2.4x 3.1x
Quick ratio 6.4x 6.2x 6.2x 5.1x 5.0x 4.8x 4.1x 2.6x 2.1x 2.7x
Capital allocation
Capex / revenue 0.8% 1.2% 2.2% 0.9% 1.4% 1.5% 0.9% 1.7% 1.0% 0.7%
Stock comp / revenue 3.6% 3.9% 3.6% 2.5% 2.7% 3.1% 3.3% 2.4% 2.2% 2.3%
Quality scores
Piotroski F-score — 4.0 7.0 4.0 3.0 4.0 2.0 2.0 5.0 4.0
Altman Z'' 10.8 10.4 10.9 8.0 7.2 7.4 5.2 1.1 1.3 2.3
Accruals ratio −4.9% −16.1% −2.5% −4.8% −9.4% −6.3% −10.3% −27.1% −13.4% −3.9%

Source: SEC EDGAR XBRL filings (CIK 0001294133). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open